Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI may help decide who gets immunotherapy after liver cancer surgery

NCT ID NCT07379489

Disease control Sponsor: Tongji Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study will test whether a deep learning computer model can help doctors decide which liver cancer patients should receive immunotherapy (PD-1 inhibitors) after surgery to prevent the cancer from returning. About 300 patients who have had their liver cancer completely removed will be followed to see if the model's recommendations improve how long they stay cancer-free. The goal is to personalize treatment based on the type of recurrence risk.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PD-1 inhibitors (a type of immunotherapy that helps the immune system attack cancer cells)
What this could lead to
If successful, this could provide a personalized way to use immunotherapy after liver cancer surgery, potentially reducing the chance of cancer coming back.
What could go wrong
This trial hasn't started yet and is relatively small (300 people). The deep learning model may not accurately predict who benefits, and PD-1 inhibitors can cause immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Dec 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The target population was patients with hepatocellular carcinoma who were undergoing curative surgery as initial treatment and who were receiving active surveillance or adjuvant PD-1 inhibitors postoperatively.

Ages

18 to 75 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged between 18 and 75; * achieved complete tumor resection; * histological verification of HCC; * liver function classified as Child-Pugh grade A or B; * No other serious systemic disease or organ dysfunction. Exclusion Criteria: * history of other malignancies or recurrent HCC; * extrahepatic metastasis; * prior treatments for HCC; * ongoing severe postoperative complications; * mixed or other types of liver cancer; * received other adjuvant therapy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adjuvant therapy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adjuvant therapy HCC Immune checkpoint inhibitor Recurrence

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.